Breast (Mar 2023)

SA 5.2 Risk assessment in ER positive disease: Who should receive CDK 4–6 inhibitors?

  • A. De Michele

Journal volume & issue
Vol. 68
p. S5

Abstract

Read online

No abstracts available.